{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:17:56Z","timestamp":1782782276422,"version":"3.54.5"},"reference-count":134,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness, New York, NY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"The National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY029409"],"award-info":[{"award-number":["R01EY029409"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS124784"],"award-info":[{"award-number":["R01NS124784"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eversight and the Michigan Economic Development Council"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tourmaline Bio"},{"DOI":"10.13039\/100018748","name":"ArgenX","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sling Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is an autoimmune disease involving periocular and orbital tissue. The manifestations of TED include proptosis, diplopia, visual disturbance, and lacrimal symptoms. Dry\/gritty eyes, light sensitivity, and tearing are prominent lacrimal system-related symptoms. They can be misdiagnosed as dry eye syndrome, chronic conjunctivitis, or allergies. Multiple therapeutic interventions can be utilized in the management of lacrimal symptoms of TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Description<\/jats:title>\n                    <jats:p>Lacrimal system dysfunction occurs from immune cell infiltration of glandular tissues as well as from poor eyelid draping causing excess exposure of the globe surface. Noninvasive treatments for lacrimal system abnormalities include local supportive measures aimed at preserving eye surface tear film, systemic and topical medications such as corticosteroids which target inflammation, and biologicals which modify immune responses. Surgical interventions can mitigate the negative impact of proptosis and poor eyelid draping on corneal exposure. These procedures include orbital decompression and eyelid repair. Nonmedical interventions include smoking cessation and patient education. Multidisciplinary care can reduce misdiagnoses, improve management, and reduce the negative impact on quality of life from TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Several treatment options are currently available to mitigate lacrimal system dysfunction in TED. More targeted therapies are emerging or have recently appeared in the clinic. Patients with mild TED can benefit from supportive care aimed at symptomatic relief. An inter-disciplinary approach to managing patients with lacrimal system abnormalities can minimize the negative impact of lacrimal insufficiency associated with TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag045","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:50:23Z","timestamp":1770295823000},"page":"e1435-e1445","source":"Crossref","is-referenced-by-count":1,"title":["Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease"],"prefix":"10.1210","volume":"111","author":[{"given":"Christian","family":"Reinhardt","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Fotovat","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Kumar","family":"Aakalu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-9685","authenticated-orcid":false,"given":"Terry J","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center , Ann Arbor, MI 48105 ,","place":["USA"]},{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"1","key":"2026042119572018600_dgag045-B1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature","volume":"9","author":"Mu\u00f1oz-Ortiz","year":"2020","journal-title":"Syst Rev"},{"issue":"16","key":"2026042119572018600_dgag045-B2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2026042119572018600_dgag045-B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves' disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119572018600_dgag045-B4","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/jc.2018-01626","article-title":"Insights into local orbital immunity: evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy","volume":"104","author":"Fang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119572018600_dgag045-B5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2024.0606","article-title":"Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy","volume":"35","author":"Smith","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"2026042119572018600_dgag045-B6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"2026042119572018600_dgag045-B7","volume-title":"StatPearls","author":"Shah","year":"2025"},{"key":"2026042119572018600_dgag045-B8","doi-asserted-by":"crossref","first-page":"1565762","DOI":"10.3389\/fopht.2025.1565762","article-title":"The burden of illness in thyroid eye disease: current state of the evidence","volume":"5","author":"Tamhankar","year":"2025","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"5","key":"2026042119572018600_dgag045-B9","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab034","article-title":"Thyroid eye disease: navigating the new treatment landscape","volume":"5","author":"Dosiou","year":"2021","journal-title":"J Endocr Soc"},{"issue":"8","key":"2026042119572018600_dgag045-B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2021.0671","article-title":"Immunophenotype of lacrimal glands in Graves orbitopathy: implications for the pathogenesis of Th1 and Th17 immunity","volume":"32","author":"Huang","year":"2022","journal-title":"Thyroid"},{"issue":"Suppl_1","key":"2026042119572018600_dgag045-B11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It takes two to Tango: IGF-I and TSH receptors in thyroid eye disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042119572018600_dgag045-B12","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1038\/s41598-018-29113-2","article-title":"Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy","volume":"8","author":"Kishazi","year":"2018","journal-title":"Sci Rep"},{"key":"2026042119572018600_dgag045-B13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jtos.2025.05.005","article-title":"The ocular surface tear film as a biomarker for systemic health","volume":"37","author":"Fotovat-Ahmadi","year":"2025","journal-title":"Ocul Surf"},{"issue":"8","key":"2026042119572018600_dgag045-B14","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1167\/iovs.13-13704","article-title":"Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy","volume":"55","author":"Huang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2026042119572018600_dgag045-B15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/IOP.0000000000002991","article-title":"Lacrimal gland fibrosis in patients with moderate-to-severe thyroid eye disease","volume":"42","author":"Yuksel","year":"2026","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"2026042119572018600_dgag045-B16","doi-asserted-by":"crossref","first-page":"e800","DOI":"10.1111\/aos.14000","article-title":"Dry eye syndrome in thyroid eye disease patients: the role of increased incomplete blinking and Meibomian gland loss","volume":"97","author":"Park","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2026042119572018600_dgag045-B17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves' orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"issue":"4","key":"2026042119572018600_dgag045-B18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II report executive summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"2026042119572018600_dgag045-B19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"2026042119572018600_dgag045-B20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"issue":"4","key":"2026042119572018600_dgag045-B21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jtos.2018.07.003","article-title":"Subjective versus objective dry eye disease in patients with moderate-severe thyroid eye disease","volume":"16","author":"Kashkouli","year":"2018","journal-title":"Ocul Surf"},{"issue":"4","key":"2026042119572018600_dgag045-B22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"2026042119572018600_dgag045-B23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III digest report","volume":"279","author":"Stapleton","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"2026042119572018600_dgag045-B24","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/jcm12093203","article-title":"The association between autoimmune thyroid disease and ocular surface damage: a retrospective population-based cohort study","volume":"12","author":"Lai","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"2026042119572018600_dgag045-B25","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2021.03.030","article-title":"Systemic conditions associated with severity of dry eye signs and symptoms in the dry eye assessment and management study","volume":"128","author":"Yu","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"2026042119572018600_dgag045-B26","doi-asserted-by":"crossref","first-page":"18849","DOI":"10.1038\/s41598-022-22580-8","article-title":"Prevalence and associations of dry eye disease and Meibomian gland dysfunction in the Ural eye and medical study","volume":"12","author":"Bikbov","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"2026042119572018600_dgag045-B27","first-page":"e32552","article-title":"Prevalence of dry eye disease and its risk factors among the general population of Saudi Arabia: a cross-sectional survey","volume":"14","author":"Dossari","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"2026042119572018600_dgag045-B28","doi-asserted-by":"crossref","first-page":"101800","DOI":"10.1016\/j.clae.2022.101800","article-title":"A cross-sectional study of non-modifiable and modifiable risk factors of dry eye disease states","volume":"46","author":"Garcia-Queiruga","year":"2023","journal-title":"Cont Lens Anterior Eye"},{"issue":"17","key":"2026042119572018600_dgag045-B29","first-page":"283","article-title":"Quality of life and occupational disability in endocrine orbitopathy","volume":"106","author":"Ponto","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2026042119572018600_dgag045-B30","doi-asserted-by":"crossref","first-page":"1283374","DOI":"10.3389\/fendo.2023.1283374","article-title":"How patients experience thyroid eye disease","volume":"14","author":"Smith","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026042119572018600_dgag045-B31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beem.2011.11.001","article-title":"Quality of life in Graves' ophthalmopathy","volume":"26","author":"Wiersinga","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2026042119572018600_dgag045-B32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.2007.03087.x","article-title":"The impact of thyroid eye disease upon patients' wellbeing: a qualitative analysis","volume":"68","author":"Estcourt","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026042119572018600_dgag045-B33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves' ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"2026042119572018600_dgag045-B34","doi-asserted-by":"crossref","first-page":"7602419","DOI":"10.1155\/2019\/7602419","article-title":"Evaluation of the Graves' Orbitopathy-specific quality of life questionnaire in the mainland Chinese population","volume":"2019","author":"Zeng","year":"2019","journal-title":"J Ophthalmol"},{"issue":"4","key":"2026042119572018600_dgag045-B35","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026042119572018600_dgag045-B36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2026042119572018600_dgag045-B37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"2026042119572018600_dgag045-B38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2265.2004.02143.x","article-title":"Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies","volume":"61","author":"Eckstein","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119572018600_dgag045-B39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","article-title":"Modification of the classification of the eye changes of Graves' disease","volume":"83","author":"Werner","year":"1977","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2026042119572018600_dgag045-B40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.1991.1.357","article-title":"Classification of the eye changes of Graves' disease","volume":"1","author":"Wiersinga","year":"1991","journal-title":"Thyroid"},{"issue":"Suppl_1","key":"2026042119572018600_dgag045-B41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1210\/clinem\/dgac230","article-title":"Measuring health-related quality of life in thyroid eye disease","volume":"107","author":"Sharma","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026042119572018600_dgag045-B42","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/clinem\/dgaf009","article-title":"Treatment of hyperthyroidism in Graves' disease complicated by thyroid eye disease","volume":"110","author":"Bartalena","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119572018600_dgag045-B43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/thy.2012.0050","article-title":"Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin","volume":"23","author":"Rosario","year":"2013","journal-title":"Thyroid"},{"issue":"7","key":"2026042119572018600_dgag045-B44","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1167\/iovs.06-1309","article-title":"Influence of thyroid hormone on thyroid hormone receptor beta-1 expression and lacrimal gland and ocular surface morphology","volume":"48","author":"Dias","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2026042119572018600_dgag045-B45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imj.15067","article-title":"Medical and surgical treatment of thyroid eye disease","volume":"52","author":"Hall","year":"2022","journal-title":"Intern Med J"},{"key":"2026042119572018600_dgag045-B46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4615-4647-4_6","volume-title":"Recent Developments in Graves' Ophthalmopathy","author":"Prummel","year":"2000"},{"issue":"8664","key":"2026042119572018600_dgag045-B47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(89)90945-8","article-title":"Ophthalmopathy and thyroid stimulation","volume":"2","author":"Karlsson","year":"1989","journal-title":"Lancet"},{"issue":"9","key":"2026042119572018600_dgag045-B48","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","article-title":"A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy","volume":"90","author":"Perros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026042119572018600_dgag045-B49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/cen.15128","article-title":"The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"101","author":"Sharabati","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2026042119572018600_dgag045-B50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrendo.2011.128","article-title":"Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy?","volume":"7","author":"Smith","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"2026042119572018600_dgag045-B51","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"2026042119572018600_dgag045-B52","volume-title":"Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids","author":"Institute of Medicine Panel on Dietary A, Related C","year":"2000"},{"issue":"3","key":"2026042119572018600_dgag045-B53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12020-023-03672-5","article-title":"Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study","volume":"84","author":"Wang","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"2026042119572018600_dgag045-B54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s42000-019-00125-5","article-title":"Selenium intake, status, and health: a complex relationship","volume":"19","author":"Rayman","year":"2020","journal-title":"Hormones (Athens)"},{"issue":"9","key":"2026042119572018600_dgag045-B55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/nu10091203","article-title":"Selenium, selenoproteins, and immunity","volume":"10","author":"Avery","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"2026042119572018600_dgag045-B56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaophthalmol.2024.6337","article-title":"Selenium vs control for Graves ophthalmopathy in a selenium-sufficient area: a randomized clinical trial","volume":"143","author":"Ahn","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"2026042119572018600_dgag045-B57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026042119572018600_dgag045-B58","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40618-019-01174-8","article-title":"Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids","volume":"43","author":"Xu","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2026042119572018600_dgag045-B59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/ceo.12317","article-title":"Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy","volume":"42","author":"Gao","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"2026042119572018600_dgag045-B60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3892\/etm.2020.9282","article-title":"Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: a single center prospective randomized trial","volume":"20","author":"Mu","year":"2020","journal-title":"Exp Ther Med"},{"issue":"1","key":"2026042119572018600_dgag045-B61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/11206721241254405","article-title":"Triamcinolone injection in the treatment of lid retraction for thyroid-associated ophthalmopathy: a systematic review","volume":"35","author":"Badjrai","year":"2025","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"2026042119572018600_dgag045-B62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/IOP.0000000000002662","article-title":"Peri-levator betamethasone versus triamcinolone injection in management of thyroid eye disease-related upper eyelid retraction without proptosis","volume":"40","author":"Awad","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"2026042119572018600_dgag045-B63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/IOP.0000000000002810","article-title":"Local betamethasone versus triamcinolone injection in management of thyroid eye disease-related upper eyelid retraction with proptosis","volume":"41","author":"Awad","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"Suppl 1","key":"2026042119572018600_dgag045-B64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000508789","article-title":"Novel approaches for immunosuppression in Graves' hyperthyroidism and associated orbitopathy","volume":"9","author":"Lee","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"6","key":"2026042119572018600_dgag045-B65","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"2026042119572018600_dgag045-B66","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"issue":"8","key":"2026042119572018600_dgag045-B67","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"issue":"18","key":"2026042119572018600_dgag045-B68","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026042119572018600_dgag045-B69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2026042119572018600_dgag045-B70","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in Longer-duration thyroid eye disease and Re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"2026042119572018600_dgag045-B71","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026042119572018600_dgag045-B72","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/thy.2023.0656","article-title":"Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials","volume":"34","author":"Kahaly","year":"2024","journal-title":"Thyroid"},{"issue":"4","key":"2026042119572018600_dgag045-B73","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ceo.14208","article-title":"Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab","volume":"51","author":"Ugradar","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"2026042119572018600_dgag045-B74","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00417-024-06491-0","article-title":"Teprotumumab improves light sensitivity in patients with thyroid eye disease","volume":"262","author":"Parunakian","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"2026042119572018600_dgag045-B75","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"issue":"7","key":"2026042119572018600_dgag045-B76","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41574-024-00995-9","article-title":"Hearing abnormalities in patients treated with teprotumumab","volume":"20","author":"Brant","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2026042119572018600_dgag045-B77","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"issue":"12","key":"2026042119572018600_dgag045-B78","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2026042119572018600_dgag045-B79","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"2026042119572018600_dgag045-B80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2026042119572018600_dgag045-B81","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1210\/clinem\/dgae711","article-title":"The efficacy and safety of intravenous tocilizumab to treat Graves' ophthalmopathy: a systematic review and single-arm meta-analysis","volume":"110","author":"Sun","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119572018600_dgag045-B82","doi-asserted-by":"crossref","first-page":"1160936","DOI":"10.3389\/fendo.2023.1160936","article-title":"Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026042119572018600_dgag045-B83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119572018600_dgag045-B84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"1 Suppl 2","key":"2026042119572018600_dgag045-B85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"2026042119572018600_dgag045-B86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves' orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"2026042119572018600_dgag045-B87","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"2026042119572018600_dgag045-B88","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1120672119845224","article-title":"The effects of rituximab on Graves'orbitopathy: a retrospective study of 14 patients","volume":"30","author":"Eid","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"2026042119572018600_dgag045-B89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119572018600_dgag045-B90","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves' orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid"},{"key":"2026042119572018600_dgag045-B91","first-page":"25158414211027760","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"2026042119572018600_dgag045-B92","first-page":"47","article-title":"The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man","volume":"8","author":"Elion","year":"1960","journal-title":"Cancer Chemother Rep"},{"issue":"3","key":"2026042119572018600_dgag045-B93","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1-2","key":"2026042119572018600_dgag045-B94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03602538508991433","article-title":"The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine","volume":"16","author":"Van Scoik","year":"1985","journal-title":"Drug Metab Rev"},{"key":"2026042119572018600_dgag045-B95","doi-asserted-by":"crossref","first-page":"1168936","DOI":"10.3389\/fendo.2023.1168936","article-title":"Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"14","author":"Allam","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042119572018600_dgag045-B96","doi-asserted-by":"crossref","first-page":"1473224","DOI":"10.3389\/fendo.2024.1473224","article-title":"Response: commentary: azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"15","author":"Allam","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026042119572018600_dgag045-B97","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5301\/ejo.5000463","article-title":"Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience","volume":"24","author":"Chalvatzis","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"2026042119572018600_dgag045-B98","doi-asserted-by":"crossref","first-page":"1342915","DOI":"10.3389\/fendo.2024.1342915","article-title":"Commentary: azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"15","author":"Mittal","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026042119572018600_dgag045-B99","first-page":"8","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4","key":"2026042119572018600_dgag045-B100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u2008 \u00d7 \u20082 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026042119572018600_dgag045-B101","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1080\/21655979.2022.2101191","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis","volume":"13","author":"Feng","year":"2022","journal-title":"Bioengineered"},{"issue":"9038","key":"2026042119572018600_dgag045-B102","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate mofetil","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"2026042119572018600_dgag045-B103","doi-asserted-by":"crossref","first-page":"788228","DOI":"10.3389\/fmed.2022.788228","article-title":"Mycophenolate mofetil (CellCept\u00ae) in combination with low dose prednisolone in moderate to severe Graves' orbitopathy","volume":"9","author":"Rajabi","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2026042119572018600_dgag045-B104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026042119572018600_dgag045-B105","first-page":"268","article-title":"Clinical efficacy of mycophenolate ester in the treatment of active thyroid-associated ophthalmopathy","volume":"28","author":"Hu","year":"2015","journal-title":"J Graduate Med Sci"},{"issue":"6","key":"2026042119572018600_dgag045-B106","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves' orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2026042119572018600_dgag045-B107","doi-asserted-by":"crossref","first-page":"1140196","DOI":"10.3389\/fendo.2023.1140196","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042119572018600_dgag045-B108","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S305717","article-title":"Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease","volume":"15","author":"Quah Qin Xian","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"2026042119572018600_dgag045-B109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2026042119572018600_dgag045-B110","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119572018600_dgag045-B111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.02.001","article-title":"Ocular surface disease in thyroid eye disease: a narrative review","volume":"24","author":"Rana","year":"2022","journal-title":"Ocul Surf"},{"issue":"4","key":"2026042119572018600_dgag045-B112","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajo.2009.09.023","article-title":"Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena)","volume":"149","author":"Vogel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2026042119572018600_dgag045-B113","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. Prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"2026042119572018600_dgag045-B114","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s40123-025-01190-3","article-title":"Real-world experience with lifitegrast ophthalmic solution in patients with dry eye disease: a provider survey in the USA and Canada","volume":"14","author":"Koetting","year":"2025","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"2026042119572018600_dgag045-B115","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1038\/s41598-024-63784-4","article-title":"Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial","volume":"14","author":"Jin","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"2026042119572018600_dgag045-B116","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/08820538.2025.2519049","article-title":"Autologous Serum tears in the management of ocular surface diseases: a comprehensive review of published evidence","volume":"41","author":"Bachtalia","year":"2026","journal-title":"Semin Ophthalmol"},{"issue":"9","key":"2026042119572018600_dgag045-B117","first-page":"6217","article-title":"Utility of PROSE in thyroid eye disease patients with recurrent proptosis after orbital decompression","volume":"60","author":"Gervasio","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"2026042119572018600_dgag045-B118","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/IOP.0000000000000934","article-title":"Utility of PROSE device in the management of Complex oculoplastic pathology","volume":"34","author":"Scofield-Kaplan","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"8","key":"2026042119572018600_dgag045-B119","first-page":"1267","article-title":"Therapeutic contact lens use in patients with thyroid eye disease at a tertiary care center","volume":"62","author":"Strauss","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2026042119572018600_dgag045-B120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.survophthal.2017.03.007","article-title":"Orbital decompression for thyroid eye disease","volume":"63","author":"Rootman","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"2026042119572018600_dgag045-B121","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12325-015-0228-y","article-title":"Critical appraisal on orbital decompression for thyroid eye disease: a systematic review and literature search","volume":"32","author":"Boboridis","year":"2015","journal-title":"Adv Ther"},{"issue":"1","key":"2026042119572018600_dgag045-B122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-0037-1598192","article-title":"Orbital decompression for thyroid eye Disease","volume":"31","author":"Braun","year":"2017","journal-title":"Semin Plast Surg"},{"issue":"4","key":"2026042119572018600_dgag045-B123","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3341\/kjo.2016.0059","article-title":"Causes and surgical outcomes of lower eyelid retraction","volume":"31","author":"Kim","year":"2017","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"2026042119572018600_dgag045-B124","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/IOP.0000000000002852","article-title":"Botulinum toxin treatment in thyroid eye disease: a systematic review and meta-analysis","volume":"41","author":"Zong","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"2026042119572018600_dgag045-B125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10792-025-03658-4","article-title":"Efficacy and safety of botulinum toxin as a non-surgical option for upper eyelid retraction in active thyroid-associated ophthalmopathy: a prospective interventional study","volume":"45","author":"Kumar","year":"2025","journal-title":"Int Ophthalmol"},{"issue":"1","key":"2026042119572018600_dgag045-B126","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1038\/s41598-025-89063-4","article-title":"Triamcinolone acetonide and botulinum toxin A for upper eyelid retraction in thyroid-associated ophthalmopathy","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"issue":"Suppl 5","key":"2026042119572018600_dgag045-B127","first-page":"S164","article-title":"Risk of smoking in thyroid-associated orbitopathy","volume":"107","author":"Mann","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"2026042119572018600_dgag045-B128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/eje.0.1460153","article-title":"Smoking and thyroid disorders\u2014a meta-analysis","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026042119572018600_dgag045-B129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eprac.2020.11.011","article-title":"Risk factors of thyroid eye disease","volume":"27","author":"Lee","year":"2021","journal-title":"Endocr Pract"},{"issue":"7","key":"2026042119572018600_dgag045-B130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.oftal.2019.03.008","article-title":"Effectiveness of oral counselling for smoke cessation in Graves orbitopathy patients","volume":"94","author":"de-Arriba-Palomero","year":"2019","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"4","key":"2026042119572018600_dgag045-B131","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2018.0665","article-title":"Knowledge of thyroid eye disease in Graves' disease patients with and without orbitopathy","volume":"29","author":"Edmunds","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"2026042119572018600_dgag045-B132","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/01676830.2017.1280057","article-title":"Management of thyroid eye disease in the United Kingdom: a multi-centre thyroid eye disease audit","volume":"36","author":"Mellington","year":"2017","journal-title":"Orbit"},{"issue":"11","key":"2026042119572018600_dgag045-B133","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group on Graves' orbitopathy (EUGOGO) centres over the period from 2000 to 2012","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2026042119572018600_dgag045-B134","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag045\/66799443\/dgag045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1435\/66799443\/dgag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1435\/66799443\/dgag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:57:43Z","timestamp":1776815863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/e1435\/8466399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":134,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag045","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,6]]}}}